Quarterly report pursuant to Section 13 or 15(d)

Collaborative and Other Agreements (Details)

v3.2.0.727
Collaborative and Other Agreements (Details)
$ in Thousands, € in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2015
USD ($)
Jun. 30, 2014
USD ($)
Jun. 30, 2015
USD ($)
Jun. 30, 2015
EUR (€)
Jun. 30, 2014
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Licensing and collaboration agreement revenue | $ $ 945 $ 1,201 $ 1,207   $ 2,164
Royalties paid, minimum (in hundredths)     0.50% 0.50%  
Royalties paid, maximum (in hundredths)     5.00% 5.00%  
Collaborative Arrangement [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Eligible milestone payments receivable       € 356.5  
Eligible milestone payments receivable under specific rights not met       633.8  
Eligible milestone payments receivable, after amendment       341.5  
Eligible milestone payments receivable under specific rights not met, after amendment       € 618.8  
Collaborative Arrangement [Member] | Servier Loan [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Future initial research and development expenses to be funded by counterparty | $     $ 50,000    
Licensing and collaboration agreement revenue | $ $ 300 $ 1,100 $ 900   $ 2,000
Collaborative Arrangement [Member] | Symplmed Pharmaceuticals [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Royalties paid, minimum (in hundredths)     3.00% 3.00%  
Royalties paid, maximum (in hundredths)     10.00% 10.00%